Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
HROW

HROW - Harrow Health Inc Stock Price, Fair Value and News

$37.62-0.03 (-0.08%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

51/100

HROW

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

51/100

HROW

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HROW Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HROW Price Action

Last 7 days

13.4%

Last 30 days

26.1%

Last 90 days

10.3%

Trailing 12 Months

20.7%

HROW RSI Chart

HROW Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HROW Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-93.72

Price/Sales (Trailing)

5.22

EV/EBITDA

114.6

Price/Free Cashflow

98.1

HROW Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HROW Fundamentals

HROW Revenue

Revenue (TTM)

268.7M

Rev. Growth (Yr)

-7.59%

Rev. Growth (Qtr)

-50.38%

HROW Earnings

Earnings (TTM)

-15.0M

Earnings Growth (Yr)

-55.24%

Earnings Growth (Qtr)

-516.57%

HROW Profitability

EBT Margin

-4.16%

Return on Equity

-52.77%

Return on Assets

-3.57%

Free Cashflow Yield

1.02%

HROW Investor Care

Shares Dilution (1Y)

4.53%

Diluted EPS (TTM)

-0.39

HROW Alerts

  • 4 major insider buys recently.
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2026268.7M000
2025212.9M227.7M250.0M272.3M
2024138.7M154.1M169.1M199.6M
202392.6M102.7M114.2M130.2M
202279.2M84.3M88.5M88.6M
202152.5M62.6M66.9M72.5M
202050.7M45.2M46.9M48.9M
201944.8M47.9M49.9M51.2M
201829.5M33.1M37.3M41.4M
201721.7M23.6M25.2M26.8M
201612.5M15.5M17.7M19.9M
20153.2M4.5M6.8M9.7M
20140001.7M
20130000
2012000100.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Harrow Health Inc

HROW
Harrow Health, Inc., an eyecare pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
 CEO
 WEBSITEharrowinc.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES217

Harrow Health Inc Frequently Asked Questions

HROW is the stock ticker symbol of Harrow Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Harrow Health Inc is 1.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, HROW's PE ratio (Price to Earnings) is -93.72 and Price to Sales (PS) ratio is 5.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HROW PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Harrow Health Inc has provided 0.255 (multiply by 100 for percentage) rate of return.